Trial Search Results

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). The phase I portion of this study is being done to find the highest dose of ABT-751 that can be given safely in combination with other chemotherapy drugs. A safe dose is one that does not result in unacceptable side effects. After a safe dose for ABT-751 given with chemotherapy has been found, the study will add additional patients to find out if ABT-751 (given at the maximal safe dose) when given with additional chemotherapy is an effective therapy for the treatment of children with relapsed ALL. It is expected that approximately 15-35 children and young adults will take part in this study.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Therapeutic Advances in Childhood Leukemia Consortium

Intervention(s):

  • Drug: ABT-751
  • Drug: dexamethasone
  • Drug: PEG-asparaginase
  • Drug: doxorubicin
  • Drug: cytarabine
  • Drug: methotrexate
  • Drug: cyclophosphamide
  • Drug: 6-thioguanine

Phase:

Phase 1

Eligibility


This is an abbreviated list...

Inclusion Criteria:

   - Patients must be less than 21 years of age to be participate in this study.

   - Patients must have relapsed acute lymphoblastic leukemia (ALL) without evidence of
   central nervous system (CNS) disease.

   - Patients must have adequate kidney, heart and liver function.

   - Must be able to swallow capsules.

Exclusion Criteria:

   - Patients who are pregnant or breast feeding.

   - Patients who have an allergy to Asparaginase products or sulfa-containing medications.

   - Patients who have an active uncontrolled infection.

   - Patients who have numbness or tingling in the hands or feet or constipation.

Ages Eligible for Study

N/A - 21 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Clare Twist
6507235535
Not Recruiting